Vaxcyte Inc
PCVX
$60.88
Closing
▼-1.17%
1D
▼-3.06%
YTD
Market cap
$6.62B
52 week high
$81.98
52 week low
$41.57
Volume
284,710
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$6.62B
Analysts' Rating
STRONG BUY
Price Target (Mean)
67
Total Analysts
8
P/E
Operating Margin
0.00%
Beta
0.94
Revenue Growth (Annual)
0.00%
52 week high
$81.98
52 week low
$41.57
Div. Yield
%
EPS Annual Growth
30.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vaxcyte Inc. is a clinical-stage vaccine company. The Company develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.
